Treatment of Iraqi People with Hyperkinetic Movement Disorders by Tetrabenazine in Relation to Genetic Polymorphism of CYP450 2D6

Authors

  • Zainab A. Abbood 1 , Shatha H. Ali 2 Nawfal M. Sheaheed3

DOI:

https://doi.org/10.37506/mlu.v20i3.1476

Keywords:

CYP 450 2D6 polymorphism, poor metabolizers (PM), intermediate metabolizers (IMs) , extensive metabolizers (EM), tetrabenazine.

Abstract

Genetic polymorphism is defined as the inheritance of a trait controlled by a single genetic locus with two

alleles in which the least common allele has a frequency of about 1% or greater. The Cytochrome P450

(CYP2D6) enzyme metabolizes about 25% of clinically used drugs from many different drug classes including

antidepressants, antipsychotics, antihypertensives, and analgesics. The CYP2D6 is a highly polymorphic

gene locus with more than 75 allelic variants, thus subjects can be classified into poor metabolizers (PM),

), intermediate metabolizers (IMs), extensive metabolizers (EM), or ultra-rapid metabolizers (UM) of a

given CYP2D6 substrate. By using pharmacogenomics, the pharmacotherapy can be optimized, thereby

increasing the treatments overall efficacy and decreasing the incidence of adverse events.

The present study is aimed to predicted phenotypes of CYP2D6 as : poor metabolizers, intermediate

metabolizers, extensive metabolizers, and ultra rapid metabolizers for tetrabenazine in patients with

hyperkinetic movement disorders compared to healthy subjects in Iraq .

The study was carried on 75 subjects participated (30 male, 45 female) ; fifty of them were with hyperkinetic

movement disorders( 25 dystonia , 25 chorea ) the reminder 25 were healthy . Genotyping of CYP2D6

gene was performed by polymerase chain reaction (PCR) conventional (allele specific method). Plasma

concentration of Tetraberazine was measured by High-performance liquid chromatography (HPLC) . Data

were collected through direct interview with the subjects besides the assessment of genetic polymorphism

of CYP 450 2D6 enzyme for Iraqi people.

The results of this study show there were a significant CYP 450 2D6 enzyme polymorphism. the number

(percentage) of subjects with CYP 450 2D6 gene polymorphisms was 17 (22.66%) of the total study population.

The number (percentage) of subjects with CYP 450 2D6*2 was 58 (76.32%), whereas, subjects with CYP450

2D6 *10 was 17 (22.66%).However , no subjects were observed with CYP 450 2D6 *4 polymorphisms in

this study. The tetrabenazine concentration with mean ± SD was 3.08± 0.231 and 2.506±0.235 ng/ml for

chorea and dystonia patients respectively , while alpha and beta dihydrotetrabenazine range was 37.72±

(2.18 ng/ml _38.13± 2.00 ng/ml ) and (21.376±0.583ng/ml_ 18.252±0.874ng/ml ) respectively .

Author Biography

Zainab A. Abbood 1 , Shatha H. Ali 2 Nawfal M. Sheaheed3

1 Researcher/ Clinical Pharmacy Department, College of Pharmacy/ University of Baghdad, Iraq, 2Prof. Dr.

Clinical Laboratory Science Department, College of Pharmacy / University of Baghdad , Iraq, 3Consultant

Neurologist Dr. Baghdad Teaching Hospital, Medical City, Baghdad/ Iraq

Published

2020-07-24

How to Cite

Zainab A. Abbood 1 , Shatha H. Ali 2 Nawfal M. Sheaheed3. (2020). Treatment of Iraqi People with Hyperkinetic Movement Disorders by Tetrabenazine in Relation to Genetic Polymorphism of CYP450 2D6. Medico Legal Update, 20(3), 660-666. https://doi.org/10.37506/mlu.v20i3.1476